Pharmabiz
 

'Discover UK Bio' to explore Indo-British research collaborations

Our Bureau, BangaloreThursday, April 21, 2005, 08:00 Hrs  [IST]

In the wake of rapid growth in the UK-India trade relations, the Bangalore Bio 2005 will see significant collaborations between the biotech companies of the two countries. In this connection an event 'Discover UK Bio' will take off on April 22, 2005 which will be inaugurated by Sir Michael Arthur, British High Commissioner. The most significant ceremony is a Contract Signing Ceremony between Zenosis & Edutech and the Government of Karnataka. The main objective of the Discover UK programme is to help empower Indian companies & employees in being able to fully understand the constantly changing, numerous & complex international regulations and compliance requirements across this disparate global market. Zenosis provides this in a 'Contextual Applicable, Economical, Risk adverse and scalable technology solution. To formally sign an agreement with EduTech as Zenosis's professional strategic marketing partner for India. Among the notable members of the Discover UK team include Trigen which is a private UK biotechnology company based in London. According to Dr. Sanjay Kakkar, CEO, Trigent, the aim is to explore collaborative opportunities in drug discovery and clinical development. Efforts will be on to evaluate the potential licensing opportunities in the field. There could also be a possibility of outsourcing for research and manufacture. Instem LSS Limited a global information solutions provider in drug development is looking at tapping Indian pre-clinical market with particular reference to the biotech sector. Manches & Co., Life Science Partners, LGC , St. John's Innovation Centre, Smi Group, Rothamsted Research, International Centre for Life Science and Concordas are among the others to initiate agreements and explore the options for attracting investments. Currently, the two major pharmaceutical companies in Bangalore with parent organisations in UK are the AstraZeneca and Glaxo SmithKline. While AstraZeneca has a full fledged research and production operations here in Bangalore, Glaxo SmithKline has opened its new Clinical Data Management and Analyses Centre as a part of its expansion plans in global development projects. According to UK High Commissioner Sir Michael Arthur, the steps taken to promote science and technology would be in the areas of Bioinformatics, drug research, clinical trails and agri-biotech. Chris Parsons, Leader of the Mission & International Trade Adviser, London International Trade Team will provide a perspective of the industry in the country. This will be followed by a presentation by Jeanette Walker, Business Development Director, ERBI - on Biotech Sector in the UK. Another Presentation by Colin Greenstreet, Chairman & Chief Executive Concordas Limited would be on UK's Expectations from India's Biotech Sector.

 
[Close]